EU/3/07/452

About

On 14 June 2007, orphan designation (EU/3/07/452) was granted by the European Commission to Trio Medicines Ltd, United Kingdom, for R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H-1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea for the treatment of gastric carcinoid.

The sponsorship was transferred to Regulis Consulting Europe Limited, Ireland, in April 2019.

Key facts

Active substance
R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H-1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea (netazepide)
Disease / condition
Treatment of gastric carcinoid
Date of first decision
14/06/2007
Outcome
Positive
EU designation number
EU/3/07/452

Review of designation

This medicine is now known as netazepide.

Sponsor's contact details

Regulis Consulting Europe Limited
The Black Church
Saint Mary's Place
Dublin 7 DO7 P4AX
Ireland
Tel: +353 1 231 4691
E-mail: admin@regulis.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating